Protein corona variation in nanoparticles revisited: A dynamic grouping strategy.
暂无分享,去创建一个
Rassoul Dinarvand | Mohammad Raoufi | Ghassem Rezaei | Seyed Mojtaba Daghighi | Ismael Haririan | Iman Yousefi | Farhad Rezaee | R. Dinarvand | Mohammad Raoufi | F. Rezaee | S. M. Daghighi | I. Haririan | I. Yousefi | Ghassem Rezaei
[1] S. Cole,et al. Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer. , 2016, Oncology letters.
[2] Davoud Ahmadvand,et al. Material properties in complement activation. , 2011, Advanced drug delivery reviews.
[3] M. Irizarry. Biomarkers of Alzheimer disease in plasma , 2004, NeuroRX.
[4] Morteza Mahmoudi,et al. Personalized protein corona on nanoparticles and its clinical implications. , 2017, Biomaterials science.
[5] J. Loo,et al. Cellular uptake of Poly‐(D,L‐lactide‐co‐glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method , 2011, Biotechnology journal.
[6] M. Papi,et al. A protein corona-enabled blood test for early cancer detection. , 2017, Nanoscale.
[7] Morteza Mahmoudi,et al. A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. , 2010, Colloids and surfaces. B, Biointerfaces.
[8] Warren C W Chan,et al. Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.
[9] Manuela Semmler-Behnke,et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration , 2011, Nanotoxicology.
[10] Raehyun Kim,et al. The importance of selecting a proper biological milieu for protein corona analysis in vitro: Human plasma versus human serum. , 2016, The international journal of biochemistry & cell biology.
[11] K. Higaki,et al. Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. , 2008, International journal of pharmaceutics.
[12] Heidi Ledford. Bankruptcy filing worries developers of nanoparticle cancer drugs , 2016, Nature.
[13] K. Langer,et al. Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] D. Choi,et al. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease , 2018, Drug delivery.
[15] M. Mahmoudi,et al. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. , 2015, Contrast media & molecular imaging.
[16] Vladimir P Torchilin,et al. Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.
[17] J. Gubbins,et al. Formation of protein corona in vivo affects drug release from temperature‐sensitive liposomes , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[18] Christine Jérôme,et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[19] W. Saltzman,et al. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. , 2009, Biomaterials.
[20] R. Müller,et al. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.
[21] Sara Linse,et al. Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid , 2010, PloS one.
[22] Morteza Mahmoudi,et al. Personalized protein coronas: a "key" factor at the nanobiointerface. , 2014, Biomaterials science.
[23] C. V. Vander Kooi,et al. Structural Mechanism of Laforin Function in Glycogen Dephosphorylation and Lafora Disease , 2015, Molecular cell.
[24] Giulio Caracciolo,et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.
[25] B. Nilsson,et al. Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. , 1993, Molecular immunology.
[26] G. Caracciolo,et al. Exploitation of nanoparticle-protein corona for emerging therapeutic and diagnostic applications. , 2016, Journal of materials chemistry. B.
[27] D. Simberg,et al. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.
[28] S. Radford,et al. Nucleation of protein fibrillation by nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[29] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[30] Albert Duschl,et al. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle , 2013, Journal of Nanobiotechnology.
[31] Bernard Cabane,et al. Protein adsorption and complement activation for di-block copolymer nanoparticles. , 2011, Biomaterials.
[32] J. Kreuter,et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[33] T. Faunce. Integrated Research into the Nanoparticle-Protein Corona: A New Focus for Safe, Sustainable and Equitable Development of Nanomedicines , 2008, Nanomedicine.
[34] K. Jain. The Role of Nanobiotechnology in the Development of Personalized Medicine , 2010, Medical Principles and Practice.
[35] G Ulrich Nienhaus,et al. Studying the protein corona on nanoparticles by FCS. , 2013, Methods in enzymology.
[36] Kenneth A Dawson,et al. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. , 2013, Journal of the American Chemical Society.
[37] Ke Xu,et al. Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface. , 2018, ACS nano.
[38] L. J. Lee,et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. , 2010, International journal of pharmaceutics.
[39] G. Hill,et al. Effects of an anabolic steroid on plasma amino acids, proteins, and body composition in patients receiving intravenous hyperalimentation. , 1983, JPEN - Journal of Parenteral and Enteral Nutrition.
[40] S. Vyas,et al. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. , 2001, Critical reviews in therapeutic drug carrier systems.
[41] Vincent M Rotello,et al. Acylsulfonamide-Functionalized Zwitterionic Gold Nanoparticles for Enhanced Cellular Uptake at Tumor pH. , 2015, Angewandte Chemie.
[42] E. Bermes,et al. Changes in plasma proteins during pregnancy. , 1978, Annals of clinical and laboratory science.
[43] P. Das,et al. Probing protein adsorption on a nanoparticle surface using second harmonic light scattering. , 2016, Physical chemistry chemical physics : PCCP.
[44] Chor Yong Tay,et al. Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood. , 2015, Chemical Society reviews.
[45] S. Bhatia,et al. Nanotechnology: emerging tools for biology and medicine , 2013, Genes & development.
[46] Kristofer J. Thurecht,et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.
[47] C. Fan,et al. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. , 2011, ACS nano.
[48] M. Tóth,et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. , 2011, Biomaterials.
[49] F. Chiti,et al. SERS Detection of Amyloid Oligomers on Metallorganic-Decorated Plasmonic Beads. , 2015, ACS applied materials & interfaces.
[50] David W. Russell,et al. SDS-Polyacrylamide Gel Electrophoresis of Proteins. , 2006, CSH protocols.
[51] Jong-Min Lim,et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics , 2017, Nature Communications.
[52] Hermann B. Frieboes,et al. Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue , 2017, Journal of Nanobiotechnology.
[53] Satya Prakash Yadav,et al. Multiple Binding Sites in Fibrinogen for Integrin αMβ2 (Mac-1)* , 2004, Journal of Biological Chemistry.
[54] R. Amal,et al. Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles. , 2014, Journal of materials chemistry. B.
[55] A. Pries,et al. Blood flow resistance during hemodilution: effect of plasma composition. , 1998, Cardiovascular research.
[56] A. Saboury,et al. Biomolecular Corona Dictates Aβ Fibrillation Process. , 2018, ACS chemical neuroscience.
[57] Arezou A Ghazani,et al. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.
[58] A. Eisen,et al. Amyotrophic lateral sclerosis: Amino acid levels in plasma and cerebrospinal fluid , 1990, Annals of neurology.
[59] S. Laurent,et al. Superparamagnetic iron oxide nanoparticles alter expression of obesity and T2D-associated risk genes in human adipocytes , 2013, Scientific Reports.
[60] M. Rösslein,et al. Personalized medicine: the enabling role of nanotechnology. , 2016, Nanomedicine.
[61] S. Stolte,et al. The nanoparticle biomolecule corona: lessons learned - challenge accepted? , 2015, Chemical Society reviews.
[62] F Atyabi,et al. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents , 2011, International journal of nanomedicine.
[63] Morteza Mahmoudi,et al. Cell "vision": complementary factor of protein corona in nanotoxicology. , 2012, Nanoscale.
[64] Xinlong Wang,et al. Influence of cell size on cellular uptake of gold nanoparticles. , 2016, Biomaterials science.
[65] Andrew J Chetwynd,et al. Current Application of Capillary Electrophoresis in Nanomaterial Characterisation and Its Potential to Characterise the Protein and Small Molecule Corona , 2018, Nanomaterials.
[66] B. Brenner. Haemostatic changes in pregnancy. , 2004, Thrombosis research.
[67] Peter Wipf,et al. Nanoparticles in cellular drug delivery. , 2009, Bioorganic & medicinal chemistry.
[68] G. Caracciolo,et al. Lipid composition: a “key factor” for the rational manipulation of the liposome–protein corona by liposome design , 2015 .
[69] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[70] E. Brun,et al. Could nanoparticle corona characterization help for biological consequence prediction? , 2014, Cancer Nanotechnology.
[71] Zhipeng Lin,et al. Probing the mechanism of plasma protein adsorption on Au and Ag nanoparticles with FT-IR spectroscopy. , 2015, Nanoscale.
[72] M. Mahmoudi. Protein corona: The golden gate to clinical applications of nanoparticles. , 2016, The international journal of biochemistry & cell biology.
[73] Luca Costantino,et al. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. , 2012, Nanomedicine.
[74] Jianjun Cheng,et al. Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.
[75] Jayanth Panyam,et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.
[76] B. Jonsson,et al. Adsorption of Human Carbonic Anhydrase II Variants to Silica Nanoparticles Occur Stepwise: Binding Is Followed by Successive Conformational Changes to a Molten-Globule-like State , 2000 .
[77] V. Puntes,et al. Physicochemical characteristics of protein-NP bioconjugates: the role of particle curvature and solution conditions on human serum albumin conformation and fibrillogenesis inhibition. , 2012, Langmuir : the ACS journal of surfaces and colloids.
[78] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[79] Hirenkumar K. Makadia,et al. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. , 2011, Polymers.
[80] Qun Huo,et al. Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment. , 2015, ACS applied materials & interfaces.
[81] G. Caracciolo,et al. The protein corona of circulating PEGylated liposomes. , 2016, Biochimica et biophysica acta.
[82] B. Morris,et al. The protein and lipid composition of the plasma of different animal species determined by zone electrophoresis and chemical analysis. , 1955, Quarterly journal of experimental physiology and cognate medical sciences.
[83] Joachim O Rädler,et al. Understanding the Kinetics of Protein–Nanoparticle Corona Formation , 2016, ACS nano.
[84] W. Parak,et al. Techniques for the experimental investigation of the protein corona. , 2017, Current opinion in biotechnology.
[85] P. Lansbury,et al. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.
[86] G. Caracciolo,et al. Analytical Methods for Characterizing the Nanoparticle–Protein Corona , 2014, Chromatographia.
[87] Giulio Caracciolo,et al. Surface chemistry and serum type both determine the nanoparticle-protein corona. , 2015, Journal of proteomics.
[88] R. Müller,et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.
[89] Sílvia A. Ferreira,et al. Biocompatibility of mannan nanogel--safe interaction with plasma proteins. , 2012, Biochimica et biophysica acta.
[90] S Gordon,et al. Macrophage receptors and immune recognition. , 2005, Annual review of immunology.
[91] M. Mahmoudi,et al. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. , 2015, Nanoscale.
[92] R. Sabaté,et al. Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration , 2017, Nanomaterials.
[93] Ran Chen. UNDERSTANDING NANOPARTICLE-CELL INTERACTION , 2012 .
[94] Bengt Fadeel,et al. Safety assessment of nanomaterials: implications for nanomedicine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[95] Massimiliano Papi,et al. Principal component analysis of personalized biomolecular corona data for early disease detection , 2018, Nano Today.
[96] Kenneth A. Dawson,et al. Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.
[97] R. Dinarvand,et al. Osmolarity: A hidden factor in Nanotoxicology , 2016, DARU Journal of Pharmaceutical Sciences.
[98] Q. Huo,et al. Developing a nanoparticle test for prostate cancer scoring , 2012, Journal of Translational Medicine.
[99] Sara Linse,et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. , 2008, Journal of the American Chemical Society.
[100] S. Pun,et al. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. , 2008, Bioconjugate chemistry.
[101] James Chen Yong Kah,et al. Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release. , 2013, ACS nano.
[102] Marina A Dobrovolskaia,et al. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[103] R. Haag,et al. Protein Corona Formation on Colloidal Polymeric Nanoparticles and Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and Drug Release Properties. , 2017, Biomacromolecules.
[104] M. Ferrari,et al. The nano-plasma interface: Implications of the protein corona. , 2014, Colloids and surfaces. B, Biointerfaces.
[105] Morteza Mahmoudi,et al. Nanotoxicology: advances and pitfalls in research methodology. , 2015, Nanomedicine.
[106] D. Marsh,et al. Interaction of human serum albumin with membranes containing polymer-grafted lipids: spin-label ESR studies in the mushroom and brush regimes. , 2002, Biochimica et biophysica acta.
[107] Chawnshang Chang,et al. Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers* , 2003, Journal of Biological Chemistry.
[108] J. Reynolds,et al. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. , 2016, Nanomedicine : nanotechnology, biology, and medicine.
[109] H. Fenniri,et al. Nanotechnology-based drug delivery systems , 2007, Journal of occupational medicine and toxicology.
[110] K. Dawson,et al. The Protein Corona Mediates the Impact of Nanomaterials and Slows Amyloid Beta Fibrillation , 2013, Chembiochem : a European journal of chemical biology.
[111] Kenneth A. Dawson,et al. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. , 2011, Nature nanotechnology.
[112] Mélanie Auffan,et al. Protein corona formation for nanomaterials and proteins of a similar size: hard or soft corona? , 2013, Nanoscale.
[113] Aniket Magarkar,et al. Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. , 2016, Biochimica et biophysica acta.
[114] Y. Zu,et al. Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.
[115] M. Grunze,et al. MOLECULAR CONFORMATION AND SOLVATION OF OLIGO(ETHYLENE GLYCOL)-TERMINATED SELF-ASSEMBLED MONOLAYERS AND THEIR RESISTANCE TO PROTEIN ADSORPTION , 1997 .
[116] N. Durán,et al. Influence of protein corona on the transport of molecules into cells by mesoporous silica nanoparticles. , 2013, ACS applied materials & interfaces.
[117] K. Landfester,et al. Exploiting the biomolecular corona: pre-coating of nanoparticles enables controlled cellular interactions. , 2018, Nanoscale.
[118] D. Rubinsztein,et al. Protein misfolding disorders and macroautophagy , 2011, Current opinion in cell biology.
[119] Min Wu,et al. Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy , 2015, Theranostics.
[120] M. Wiemann,et al. Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA) , 2013, Journal of Nanoparticle Research.
[121] Wolfgang J Parak,et al. A Decade of the Protein Corona. , 2017, ACS nano.
[122] V. Torchilin,et al. Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .
[123] Y. M. Thasneem,et al. Glucosylated polymeric nanoparticles: a sweetened approach against blood compatibility paradox. , 2013, Colloids and surfaces. B, Biointerfaces.
[124] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[125] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[126] Alexander M. Seifalian,et al. Toxicology and clinical potential of nanoparticles , 2011, Nano today.
[127] Raimo Hartmann,et al. Temperature: the "ignored" factor at the NanoBio interface. , 2013, ACS nano.
[128] M. Mahmoudi,et al. Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. , 2016, ACS applied materials & interfaces.
[129] Warren C W Chan,et al. Nanoparticle-blood interactions: the implications on solid tumour targeting. , 2015, Chemical communications.
[130] C. Duvall,et al. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol. , 2017, ACS nano.
[131] Iseult Lynch,et al. The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.
[132] Si-Shen Feng,et al. Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. , 2007, Biomaterials.
[133] Stefan Tenzer,et al. Quantitative profiling of the protein coronas that form around nanoparticles , 2014, Nature Protocols.
[134] Tomasz Jetka,et al. Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells , 2015, Aging.
[135] M. Mahmoudi,et al. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. , 2016, Biomaterials.
[136] Michael Maskos,et al. Protein corona – from molecular adsorption to physiological complexity , 2015, Beilstein journal of nanotechnology.
[137] Valerie M. Weaver,et al. A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.
[138] Wolfgang J. Parak,et al. Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications , 2014 .
[139] C. Xiang,et al. Effects of donors' age and passage number on the biological characteristics of menstrual blood-derived stem cells. , 2015, International journal of clinical and experimental pathology.
[140] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[141] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[142] Morteza Mahmoudi,et al. Emerging understanding of the protein corona at the nano-bio interfaces , 2016 .
[143] Joo-Youp Lee,et al. Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin®-conjugated PLGA-PEG nanoparticles for drug delivery. , 2018, Colloids and surfaces. B, Biointerfaces.
[144] B. Liedberg,et al. Component-Specific Analysis of Plasma Protein Corona Formation on Gold Nanoparticles Using Multiplexed Surface Plasmon Resonance. , 2016, Small.
[145] Ventola Cl,et al. Progress in Nanomedicine: Approved and Investigational Nanodrugs. , 2017 .
[146] Bessi Qorri,et al. Recent advances in “smart” delivery systems for extended drug release in cancer therapy , 2018, International journal of nanomedicine.
[147] Sara Linse,et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[148] R. Pawar,et al. In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link? , 2017, Biotechnology advances.
[149] Wolfgang J Parak,et al. Effects of surface functionalization on the adsorption of human serum albumin onto nanoparticles – a fluorescence correlation spectroscopy study , 2014, Beilstein journal of nanotechnology.
[150] Philip J. Smith,et al. Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization , 2012, International journal of nanomedicine.
[151] C. Dobson,et al. Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.
[152] Kenneth A. Dawson,et al. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.
[153] Aristidis Tsatsakis,et al. Protein bio-corona: critical issue in immune nanotoxicology , 2016, Archives of Toxicology.
[154] C. K. Nandi,et al. Controlling the Fate of Protein Corona by Tuning Surface Properties of Nanoparticles , 2013 .
[155] Thomas J Webster,et al. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity , 2014, International journal of nanomedicine.
[156] Balu Ranganathan,et al. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. , 2008, Biomaterials.
[157] Morteza Mahmoudi,et al. Debugging Nano-Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies. , 2018, Trends in biotechnology.
[158] Juan Li,et al. A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours , 2016, Journal of drug targeting.
[159] Ruedi Aebersold,et al. Quantitative variability of 342 plasma proteins in a human twin population , 2015 .
[160] M. Mahmoudi,et al. Plasma concentration gradient influences the protein corona decoration on nanoparticles , 2013 .
[161] Svetlana Gelperina,et al. Adsorption of plasma proteins on uncoated PLGA nanoparticles. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[162] S. Mandava,et al. In Vitro/In Vivo Toxicity Evaluation and Quantification of Iron Oxide Nanoparticles , 2015, International journal of molecular sciences.
[163] M. Mahmoudi,et al. Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.
[164] D. Jaillard,et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. , 2005, Bioconjugate chemistry.
[165] Christoffer Åberg,et al. Mapping protein binding sites on the biomolecular corona of nanoparticles. , 2015, Nature nanotechnology.
[166] Wolfgang J Parak,et al. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. , 2009, Nature nanotechnology.
[167] W. Jiskoot,et al. Measurement of the average mass of proteins adsorbed to a nanoparticle by using a suspended microchannel resonator. , 2015, Journal of pharmaceutical sciences.
[168] Urs O. Häfeli,et al. Crucial Ignored Parameters on Nanotoxicology: The Importance of Toxicity Assay Modifications and “Cell Vision” , 2012, PloS one.
[169] M. Mahmoudi,et al. Protein fibrillation and nanoparticle interactions: opportunities and challenges. , 2013, Nanoscale.
[170] K. Landfester,et al. Protein corona change the drug release profile of nanocarriers: the "overlooked" factor at the nanobio interface. , 2014, Colloids and surfaces. B, Biointerfaces.
[171] Francesco Salvatore,et al. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. , 2016, Nanomedicine.
[172] Alaaldin M. Alkilany,et al. Protein corona: Opportunities and challenges. , 2016, The international journal of biochemistry & cell biology.
[173] Albert Duschl,et al. Time evolution of the nanoparticle protein corona. , 2010, ACS nano.
[174] G. Caracciolo,et al. Stealth effect of biomolecular corona on nanoparticle uptake by immune cells. , 2015, Langmuir : the ACS journal of surfaces and colloids.
[175] Giulio Caracciolo,et al. Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. , 2014, Colloids and surfaces. B, Biointerfaces.
[176] K. Landfester,et al. Visualization of the protein corona: towards a biomolecular understanding of nanoparticle-cell-interactions. , 2017, Nanoscale.
[177] M. Platt,et al. Characterisation of the protein corona using tunable resistive pulse sensing: determining the change and distribution of a particle’s surface charge , 2016, Analytical and Bioanalytical Chemistry.
[178] Wolfgang J. Parak,et al. Protein corona formation around nanoparticles – from the past to the future , 2014 .
[179] M. Coelho,et al. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. , 2016, Colloids and surfaces. B, Biointerfaces.
[180] Artur Bednarkiewicz,et al. Upconverting nanoparticles: assessing the toxicity. , 2015, Chemical Society reviews.
[181] Christine Jérôme,et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[182] Kenneth A. Dawson,et al. Transferrin Coated Nanoparticles: Study of the Bionano Interface in Human Plasma , 2012, PloS one.
[183] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[184] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[185] M. Mahmoudi,et al. Graphene oxide strongly inhibits amyloid beta fibrillation. , 2012, Nanoscale.
[186] Mauro Ferrari,et al. Shrinkage of pegylated and non-pegylated liposomes in serum. , 2014, Colloids and surfaces. B, Biointerfaces.
[187] Samir Mitragotri,et al. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.
[188] Raimo Hartmann,et al. Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. , 2015, ACS nano.
[189] G. Caracciolo,et al. The biomolecular corona of nanoparticles in circulating biological media. , 2015, Nanoscale.
[190] M. Mahmoudi,et al. Protein corona composition of gold nanoparticles/nanorods affects amyloid beta fibrillation process. , 2015, Nanoscale.
[191] Sara Linse,et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.
[192] B. Ruozi,et al. Protein corona and nanoparticles: how can we investigate on? , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[193] Ruhong Zhou,et al. Towards understanding of nanoparticle–protein corona , 2015, Archives of Toxicology.
[194] Vera Ignjatovic,et al. Age-Related Differences in Plasma Proteins: How Plasma Proteins Change from Neonates to Adults , 2011, PloS one.
[195] Ravi S Kane,et al. Antifouling Coatings: Recent Developments in the Design of Surfaces That Prevent Fouling by Proteins, Bacteria, and Marine Organisms , 2011, Advanced materials.
[196] Vicki Stone,et al. Efficacy of Simple Short-Term in Vitro Assays for Predicting the Potential of Metal Oxide Nanoparticles to Cause Pulmonary Inflammation , 2008, Environmental health perspectives.
[197] Warren C W Chan,et al. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.
[198] Si-Shen Feng,et al. Nanoparticles of biodegradable polymers for new-concept chemotherapy , 2004, Expert review of medical devices.
[199] James E Bear,et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. , 2012, Nano letters.
[200] M. Mahmoudi,et al. Cell shape affects nanoparticle uptake and toxicity: An overlooked factor at the nanobio interfaces. , 2018, Journal of colloid and interface science.